Medpredict, Feb 2010, Pages: 146
amongst the most important mechanisms in development for ovarian cancer. Executive Summary
Top-Ten Report Highlights
- Key Findings
- Ovarian Cancer Standards of Care / Unmet Needs
- Subtypes
Datamonitor, Nov 2011, Pages: 166
)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Sprycel (dasatinib; Bristol-Myers Squibb)
Drug profile
John Wiley and Sons Ltd, July 2010, Pages: 564
Born out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending
John Wiley and Sons Ltd, Nov 2009, Pages: 526
inhibitors are in clinical development.
In one comprehensive volume, the editors, Dr. Rongshi Li and Dr. Jeffrey Stafford, present timely and important case studies of marketed kinase drugs and several
Informa Healthcare, Dec 2006, Pages: 176
Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety
Datamonitor, Oct 2011, Pages: 100
blockbuster targeted therapies will undergo patent expiries and the market will become more fragmented as new targeted therapies are developed for niche populations.
Features and benefits
- Sales forecasts
John Wiley and Sons Ltd, Nov 2010, Pages: 456
developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.
Topics include:
- Targeted therapy, e.g. tyrosine kinase
GlobalData, June 2011, Pages: 82
disease markets in the long run.
Reasons to buy
The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
- Develop business strategies
Informa Healthcare, Jan 2006, Pages: 822
levels of the industry and recent developments.
Scrip Yearbook 2007 will help you to:
- Identify which significant mergers and acquisitions were completed
- Analyse the strategic and financial
